Detection of squamous cell carcinoma antigen with two systems in the follow-up of patients with cervical cancer

International Journal of Biological Markers

Volumn 28, Issue 3, 2013, Pages 313-317

  Sandri, Maria Teresa ^a   Salvatici, Michela ^a   Mauro, Cristian ^a   Radice, Davide ^a   Lentati, Paola ^a   Massaro, Maria A ^a   Boveri, Sara ^a   Zorzino, Laura ^a   Landoni, Fabio ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Cervical cancer; Methods comparison; Squamous cell carcinoma antigen; Tumor markers

Indexed keywords

SQUAMOUS CELL CARCINOMA ANTIGEN; SERINE PROTEINASE INHIBITOR; SQUAMOUS CELL CARCINOMA-RELATED ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROPARTICLE ENZYME IMMUNOASSAY; PROSPECTIVE STUDY; UTERINE CERVIX CANCER; CARCINOMA, SQUAMOUS CELL; METABOLISM; MIDDLE AGED; PATHOLOGY; UTERINE CERVICAL NEOPLASMS;

ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CARCINOMA, SQUAMOUS CELL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SERPINS; UTERINE CERVICAL NEOPLASMS;

EID: 84885928241     PISSN: 03936155     EISSN: 17246008     Source Type: Journal    
DOI: 10.5301/JBM.5000031     Document Type: Article

References (24)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001; 37 S8: 4-66.
2. Cancer Statistics Working Group, 2010. United States Cancer Statistics 1999-2008 Incidence and Mortality Web-based Report. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, Atlanta.
3. Bonfrer JMG, Duffy MJ, Radtke M, et al. Tumour markers in gynaecological cancers: EGTM recommendations. Anticancer Res 1999; 19: 2807-10.
4. Kato H, Torigoe T. Radioimmunoassay for tumor antigen of human cervical squamous cell carcinoma. Cancer 1977; 40: 1621-8.
5. Suminami Y, Kishi F, Sekiguchi K, Kato H. Squamous cell carcinoma antigen is a new member of the serine protease inhibitors. Biochem Biophys Res Comm 1991; 181: 51-8.
6. Murakami A, Suminami Y, Hirakawa H, Nawata S, Numa F, Kato H. Squamous cell carcinoma antigen suppresses radiationinduced cell death. Br J Cancer 2001; 84: 851-8.
7. Murakami A, Suminami Y, Sakaguchi Y, et al. Specific detection and quantitation of SCC antigen 1 and SCC antigen 2 mRNAs by fluorescence-based asymmetric semi-nested reverse transcription PCR. Tumor Biol 2000; 21: 224-34.
8. Crombach G, Scharl A, Vierbuchen M, Wurz H, Bolte A. Detection of squamous cell carcinoma antigen in normal squamous epithelia and in squamous cell carcinomas of the uterine cervix. Cancer 1989; 63: 1337-42.
9. Trapé J, Filella X, Alsina-Donadeu M, Juan-Pereira L, Bosch- Ferrer Á, Rigo-Bonnin R. Increased plasma concentrations of tumour markers in the absence of neoplasia. Clin Chem Lab Med 2011; 49: 1605-20.
10. Kosugi S, Nishimaki T, Kanda T, Nakagawa S, Ohashi M, Hatakeyama K. Clinical significance of serum carcinoembryonic antigen, carbohydrate antigen 19-9, and squamous cell carcinoma antigen levels in esophageal cancer patients. World J Surg 2004; 28: 680-5.
11. Molina R, Filella X, Augé JM, et al. Tumor markers (CEA, CA 125, CYFRA 21-1, SCC and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 2003; 24: 209-18.
12. Ayude D, Gacio G, Páez de la Cadena M, et al. Combined use of established and novel tumour markers in the diagnosis of head and neck squamous cell carcinoma. Oncol Rep 2003; 10: 1345-50.
13. Petrelli NJ, Palmer M, Herrera L, Bhargava A. The utility of squamous cell carcinoma antigen for the follow-up of patients with squamous cell carcinoma of the anal canal. Cancer 1992; 70: 35-9.
14. Sturgeon CM, Duffy MJ, Hofmann BR, et al. Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem 2010; 56: 1-48.
15. Duk JM, Groenier KH, de Bruijn HW, et al. Pretreatment serum squamous cell carcinoma antigen: a newly identified prognostic factor in early-stage cervical carcinoma. J Clin Oncol 1996; 14: 111-8.
16. Holloway RW, To A, Moradi M, Boots L, Watson N, Shingleton HM. Monitoring the course of cervical carcinoma with the squamous cell carcinoma serum radioimmunoassay. Obstet Gynecol 1989; 74: 944-9.
17. Gaarenstroom KN, Kenter GG, Bonfrer JM, Korse CM, van dV Fleuren GJ, Trimbos JB. Can initial serum Cyfra 21-1, SCC antigen, and TPA levels in squamous cell cervical cancer predict lymph node metastases or prognosis? Gynecol Oncol 2000; 77: 164-70.
18. Scambia G, Benedetti Panici P, Foti E, et al. Squamous cell carcinoma antigen: prognostic significance and role in the monitoring of neoadjuvant chemotherapy response in cervical cancer. J Clin Oncol 1994; 12: 2309-16.
19. Gadducci A, Tana R, Cosio S, Genazzani AR. The serum assay of tumour markers in the prognostic evaluation, treatment monitoring and follow-up of patients with cervical cancer a review of the literature. Crit Rev Oncol Hematol 2008; 66: 10-20.
20. Brioschi PA, Bischof P, Delafosse C, Krauer F. Squamous-cell carcinoma antigen (SCC-A) values related to clinical outcome of pre-invasive and invasive cervical carcinoma. Int J Cancer 1991; 47: 376-9.
21. Bolli JA, Doering DL, Bosscher JR, et al. Squamous cell carcinoma antigen: clinical utility in squamous cell carcinoma of the uterine cervix. Gynecol Oncol 1994; 55: 169-73.
22. Chan YM, Ng TY, Wong LC. Monitoring of serum squamous cell carcinoma antigen levels in invasive cervical cancer: is it cost-effective? Gynecol Oncol 2002; 84: 7-11.
23. Forni F, Ferrandina G, Deodato F, et al. Squamous cell carcinoma antigen in follow-up of cervical cancer treated with radiotherapy: evaluation of cost-effectiveness. Int J Radiation Onclogy Biol Phys 2007; 69: 1145-9.
24. Chang TC, Law KS, Hong JH, et al. Positron emission tomography for unexplained elevation of serum squamous cell carcinoma antigen levels during follow-up for patients with cervical malignancies: a phase II study. Cancer 2004; 101: 164-71.